Bioventus/$BVS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Bioventus
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
- Ticker
- $BVS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 950
- Headquarters
- Durham, United States
- Website
- www.bioventus.com
Bioventus Metrics
BasicAdvanced
$1B
19.01
$0.78
0.65
-
Price and volume
Market cap
$1B
Beta
0.65
52-week high
$15.89
52-week low
$6.47
Average daily volume
424K
Financial strength
Current ratio
1.689
Quick ratio
1.107
Long term debt to equity
0.868
Total debt to equity
0.951
Interest coverage (TTM)
3.05%
Profitability
EBITDA (TTM)
80.145
Gross margin (TTM)
68.65%
Net profit margin (TTM)
9.36%
Operating margin (TTM)
10.42%
Effective tax rate (TTM)
-59.11%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
5.49%
Return on equity (TTM)
25.68%
Valuation
Price to earnings (TTM)
19.012
Price to revenue (TTM)
1.72
Price to book
4.44
Price to tangible book (TTM)
-7.79
Price to free cash flow (TTM)
10.612
Free cash flow yield (TTM)
9.42%
Free cash flow per share (TTM)
1.401
Growth
Revenue change (TTM)
3.14%
Earnings per share change (TTM)
-6,989.26%
3-year revenue growth (CAGR)
4.45%
3-year earnings per share growth (CAGR)
-44.44%
What the Analysts think about Bioventus
Analyst ratings (Buy, Hold, Sell) for Bioventus stock.
Analyst projections of the future price of Bioventus stock.
Bulls say / Bears say
Pain Treatments grew 11.5% in the second quarter, led by strong volume growth in Durolane. That helped lift total revenue by 4%. (GlobeNewswire)
Bioventus expects sales to grow 6%–7% in 2026 and sees faster second-half growth from its PNS and PRP products. If adoption continues to build, these newer offerings could broaden growth beyond its established pain franchise. (The Motley Fool)
The company repaid $45.8 million of debt in the first half and had reduced net leverage below 2× by the end of the second quarter. Continued cash generation could lower interest costs and strengthen its balance sheet. (GlobeNewswire)
Growth was uneven: Surgical Solutions revenue fell 4.5% in the second quarter and Restorative Therapies also declined. Weakness outside Pain Treatments leaves the overall growth story reliant on one leading segment. (GlobeNewswire)
Reported second-quarter net income included a $24.6 million benefit from releasing a deferred-tax valuation allowance. Adjusted earnings per share rose only 5%, so the headline profit increase overstates the improvement in underlying earnings. (GlobeNewswire)
Medicare changed reimbursement and billing rules for non-invasive bone growth stimulators, including Bioventus’s Exogen device. The company said the 2026 effect should not be material, but warned that further reimbursement changes could affect its outlook over time. (StreetInsider)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
Bioventus Financial Performance
Revenues and expenses
Bioventus Earnings Performance
Company profitability
Upcoming events
No upcoming events
Bioventus News
AllArticlesVideos
Funds containing Bioventus
Fund name | Fund size | $BVS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.